SOUTHERN JOURNAL OF SCIENCES

Background: The University of Ilorin, founded in 1975 in Nigeria, has evolved from 3 to 16 faculties, becoming the country's most sought-after institution for the past two decades. Aims: To document the institutional evolution, identify the most demanded programs, assess scientific output, examine internationalization strategies, and understand strategic development objectives. Methods: Structured interview with Vice-Chancellor Dr. Olubumi Abayomi Omotesho, following a standardized protocol covering historical, academic, scientific, and strategic aspects of the institution, under Creative Commons license format. Results: The university expanded to 16 faculties in 49 years. The most demanded programs are Medicine and Nursing, followed by Pharmacy, Law, Engineering, and Accounting. Areas with the highest scientific output: Medicine, Biological/Agricultural Sciences, and Engineering. It offers 340 postgraduate programs with approximately 7,523 students. There is a dedicated infrastructure for internationalization, with plans for international accommodations. Discussion: The predominance of healthcare courses reflects global employability trends. Research aligned with Sustainable Development Goals demonstrates a contemporary vision. The institutional goal (number one in Nigeria, top 10 in Africa, top 500 globally) shows a measurable strategic approach. Commitment to internationalization aligns with global education trends. Conclusions: The institution exemplifies an evolving African university focused on academic excellence, scientific relevance, and internationalization. The prioritization of student-centered development, clear positioning goals, and international collaboration initiatives establish solid foundations for its contribution to regional and global knowledge.

Background: The American food regulatory landscape has historically been influenced by industry interests, resulting in the widespread use of petroleum-derived synthetic food dyes banned in European countries. Chronic disease rates in American children have increased from 3% in the 1960s to approximately 60% currently, with annual healthcare costs reaching $1 trillion. The appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services marks a paradigmatic shift toward transparency and industry accountability in food safety regulation. Aim: This forum analysis examines Kennedy Jr.'s revolutionary approach to food safety regulation, particularly his confrontational stance against petroleum-based food additives exemplified by his statement, "if they want to eat petroleum, they should add it themselves at home" and evaluates the broader implications for American public health policy and global regulatory standards. Methods: Critical analysis of Kennedy Jr.'s public policy statements, examination of epidemiological data trends, and evaluation of proposed regulatory frameworks through content analysis of official speeches and policy declarations from the Department of Health and Human Services. Results: Kennedy Jr.'s administration targets the systematic elimination of synthetic food dyes through industry partnerships, scientific transparency initiatives, and restoration of rigorous research standards. His confrontational rhetorical approach, compared to Mike Tyson's boxing style, has generated unprecedented industry cooperation with food companies "calling almost daily" seeking compliance guidance. The strategy combines voluntary industry agreements with open-source information databases and enhanced FOIA access. Discussion: This confrontational rhetoric represents unprecedented directness in health policy communication, challenging decades of established regulatory practices. The approach prioritizes scientific transparency over diplomatic language, generating both media attention and voluntary industry engagement that traditional regulatory pressure failed to achieve. Conclusions: Kennedy Jr.'s revolutionary stance may establish new global standards for food additive oversight, prioritizing public health over commercial interests through evidence-based policymaking and industry accountability measures. This paradigm shift from reactive to preventive regulatory models could influence international food safety governance and restore American leadership in global health policy.

Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous hematological malignancy predominantly affecting individuals under 20 years of age. Traditional chemotherapy, such as clofarabine, has shown efficacy; however, novel immunotherapeutic strategies like tisagenlecleucel (Kymriah®) have significantly altered the treatment paradigm. Aim: This study aimed to perform a comparative analysis of tisagenlecleucel, a CAR-T cell therapy, and clofarabine, a second-generation purine nucleoside analog, evaluating their mechanisms of action, therapeutic benefits, limitations, and clinical applicability across diverse patient populations. Methods: A systematic comparative evaluation was conducted, encompassing pharmacological characteristics, mechanisms of action, treatment protocols, efficacy, safety profiles, and clinical indications of both agents. The analysis considered pharmacokinetic and pharmacodynamic data and included patient demographic variables. Results: Tisagenlecleucel demonstrated high efficacy in refractory B-cell ALL, with durable responses and a blood half-life of 128 days, but with notable immune-related adverse effects such as cytokine release syndrome. Clofarabine, effective across a broader patient population, acts via multiple antitumor mechanisms but carries significant toxicity risks, including infection and sepsis. Discussion: The therapies present distinct clinical profiles: tisagenlecleucel offers targeted immunotherapy with high specificity but requires specialized infrastructure and management of immune toxicities. Clofarabine is more widely accessible and applicable, but is associated with conventional chemotherapy-related side effects. Treatment accessibility and cost differ markedly between the two. Conclusions: Therapy selection should be personalized based on patient-specific factors and institutional resources. Tisagenlecleucel is ideal for pediatric and young adult patients with relapsed/refractory B-cell ALL in CAR-T-capable centers, while clofarabine remains a viable option for broader ALL populations, particularly when genetic therapies are not feasible. Further research is needed to optimize therapeutic strategies and improve access to advanced treatments.